TY - JOUR
T1 - TGF-β, T-cell tolerance and anti-CD3 therapy
AU - Bommireddy, Ramireddy
AU - Doetschman, Thomas
PY - 2004/1
Y1 - 2004/1
N2 - Recent studies by Chatenoud and co-workers suggest that non-mitogenic F(ab′)2 fragments of anti-CD3 antibodies, which cannot bind the Fc receptor, induce a prolonged period of tolerance and prevent diabetes in nonobese diabetic (NOD) mice. Tolerance is established by regulatory T cells through the production of transforming growth factor-β1 (TGF-β1), but the mechanism by which TGF-β1 confers this activity is unclear. Analysis of mice deficient in TGF-β1 suggests that TGF-β1 raises the threshold at which intracellular calcium activates T cells to a level that prevents an autoimmune response.
AB - Recent studies by Chatenoud and co-workers suggest that non-mitogenic F(ab′)2 fragments of anti-CD3 antibodies, which cannot bind the Fc receptor, induce a prolonged period of tolerance and prevent diabetes in nonobese diabetic (NOD) mice. Tolerance is established by regulatory T cells through the production of transforming growth factor-β1 (TGF-β1), but the mechanism by which TGF-β1 confers this activity is unclear. Analysis of mice deficient in TGF-β1 suggests that TGF-β1 raises the threshold at which intracellular calcium activates T cells to a level that prevents an autoimmune response.
UR - http://www.scopus.com/inward/record.url?scp=0742269689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0742269689&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2003.11.007
DO - 10.1016/j.molmed.2003.11.007
M3 - Short survey
C2 - 14720578
AN - SCOPUS:0742269689
SN - 1471-4914
VL - 10
SP - 3
EP - 9
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 1
ER -